A two-tier utilisation-management landscape, topical step-therapy before biologics and prior-biologic step-edits before JAKs, sits atop a stable Dupixent price that ICER judged value-aligned and the IRA has not touched.
US commercial payers manage the moderate-to-severe atopic dermatitis market through layered step therapy. Dupilumab and other IL-4Rα / IL-13 biologics require documented failure, intolerance, or contraindication to topical therapy, typically a medium-to-high-potency topical corticosteroid and/or calcineurin inhibitor over 2–4 weeks, before approval, verified in UHC and Cigna coverage policies. Oral JAK inhibitors (upadacitinib, abrocitinib) sit a tier lower: following the FDA's 2022 JAK-class boxed warning for malignancy, thrombosis, and major adverse cardiovascular events, major payers (UHC, CVS/Aetna, Cigna) require prior failure of a biologic before granting JAK access, confining the class to second-line despite superior short-term efficacy benchmarks.
On value, ICER has assessed atopic dermatitis twice. Its 2017 review judged dupilumab to be introduced at a price aligned with its added benefit (approximately $31,000 net; within the $50,000–$150,000 per-QALY threshold), and its 2021 review of oral JAK inhibitors found abrocitinib and upadacitinib effective but flagged class safety concerns, setting health-benefit price benchmarks of roughly $21,400–$41,800 per year and calling for upadacitinib discounts of 35–63% off list. Dupixent's list price sits near $3,900–$4,200 per 4-week supply (approximately $37,000 net annually). On the IRA, Dupixent, a high-spend Part D self-injectable, does not appear on any published CMS selected-drug list (IPAY 2026, 2027, or 2028, the last announced January 2026 and the first to include Part B drugs); it remains negotiation-eligible in future cycles but has not been selected.
US atopic dermatitis agent payer & HTA status — 2026
| Drug (Brand / INN) | Class | Benefit Routing | Step-Therapy / PA Gate | ICER / HTA View | IRA Status |
|---|---|---|---|---|---|
| Dupixent (dupilumab) | IL-4Rα mAb | Medicare Part D (self-injected SC) | Prior topical corticosteroid/calcineurin-inhibitor failure (2–4 wks); specialist Rx | ICER 2017: priced in alignment with benefit (~$31K net; within threshold) | Not selected — absent from CMS lists IPAY 2026–2028 |
| Rinvoq (upadacitinib) | JAK1 inhibitor (oral) | Medicare Part D | Prior biologic failure required; boxed-warning PA gate | ICER 2021: effective; 35–63% discount to reach threshold; safety flag | Not selected — IPAY 2026–2028 |
| Cibinqo (abrocitinib) | JAK1 inhibitor (oral) | Medicare Part D | Prior biologic failure required; boxed-warning PA gate | ICER 2021: effective; class safety concerns; benchmark $21.4K–$41.8K/yr | Not selected — IPAY 2026–2028 |
| Adbry (tralokinumab) | IL-13 mAb | Medicare Part D (SC) | Prior topical failure; often non-preferred vs dupilumab | ICER 2021: unlikely more efficacious than dupilumab | Not selected — IPAY 2026–2028 |
Sources: ICER Atopic Dermatitis Final Evidence Reports — 2017 (dupilumab/crisaborole) and 2021 (JAK inhibitors, tralokinumab); FDA boxed-warning prescribing information (2022 JAK class update); UHC, CVS/Aetna, and Cigna Dupixent and JAK coverage policy documents; CMS Medicare Drug Price Negotiation Program selected-drug lists (IPAY 2026–2028); Sanofi/Regeneron WAC disclosure.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Current topical step-therapy requirements for biologics (agent, potency, duration)
- prior-biologic step-edit criteria for upadacitinib and abrocitinib
- specialist-prescriber requirements
- commercial vs Medicare Part D tier positioning
Delivers
- ICER 2017 dupilumab cost-effectiveness verdict
- ICER 2021 JAK inhibitor health-benefit price benchmarks and required discounts
- safety-driven policy recommendations for prior authorization
- payer use of ICER benchmarks in formulary design
Delivers
- Dupixent WAC and net-price analysis
- Part D benefit routing and patient OOP under the redesigned benefit
- CMS selected-drug-list status (IPAY 2026–2028) and future negotiation eligibility
- boxed-warning impact on JAK formulary economics
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How dupilumab, tralokinumab, and JAK inhibitors route through Medicare Part D and commercial pharmacy benefits at UHC, CVS/Aetna, and Cigna
- Why the topical-then-biologic-then-JAK sequence structures utilization management across the moderate-to-severe AD market
- The 2-4 week topical corticosteroid or calcineurin-inhibitor trial UHC and Cigna require before approving dupilumab
- Specialist-prescriber requirements and the non-preferred tier placement gating Adbry (tralokinumab) behind Dupixent
- How the FDA's 2022 boxed warning for malignancy, thrombosis, and MACE pushed upadacitinib and abrocitinib into second-line status
- Why UHC, CVS/Aetna, and Cigna all require documented prior-biologic failure before authorizing Rinvoq or Cibinqo
- ICER's 2017 finding that dupilumab's ~$31,000 net price fell within the $50,000-$150,000 per-QALY threshold
- ICER's 2021 verdict on abrocitinib and upadacitinib: effective but requiring 35-63% discounts to meet $21,400-$41,800 benchmarks
- Dupixent's WAC of $3,900-4,200 per 4-week supply, translating to roughly $37,000 in net annual cost
- Why Dupixent remains absent from every CMS IRA selected-drug list through IPAY 2028, announced January 2026
- Payer-by-payer PA criteria compared across UHC, CVS/Aetna, Cigna, Anthem, and Humana formulary policies
- Where step-therapy duration and specialist-prescriber rules diverge across the five largest US commercial payers
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Atopic dermatitis P&HTA is built from ICER evidence reports, CMS IRA negotiation documentation, published WAC disclosures, and live payer formulary and PA policy documents from UHC, CVS/Aetna, Cigna, Anthem, and Humana.
Key sources: ICER Atopic Dermatitis Final Evidence Reports (2017 dupilumab/crisaborole; 2021 JAK inhibitors and tralokinumab); FDA JAK-class boxed-warning prescribing information (2022); CMS Medicare Drug Price Negotiation Program selected-drug lists (IPAY 2026–2028); Sanofi/Regeneron WAC disclosures; major payer PA clinical coverage policies (current versions).
- Step-therapy and PA criteria verified against current UHC and Cigna Dupixent coverage policy documents and JAK inhibitor coverage policies
- JAK inhibitor boxed-warning access gate verified against FDA-approved prescribing information (2022 class update) and payer step-edit policies
- ICER value verdicts verified against ICER Atopic Dermatitis Final Evidence Reports (2017 and 2021)
- Dupixent IRA status verified against CMS published selected-drug lists (IPAY 2026, 2027, 2028); not selected as of the January 2026 IPAY 2028 announcement
- Dupixent WAC verified against Sanofi/Regeneron published price disclosures
Frequently asked questions
Commission this assessment
AXLRx US Atopic Dermatitis Payer & HTA is built for market access, HEOR, and pricing teams navigating topical-to-biologic step therapy, the JAK black-box access gate, ICER's value verdicts, and Dupixent's IRA exposure. Custom assessment in 72 hours.
Specify indication, payer focus (step therapy, ICER, IRA/PA criteria), and commercial question.
AXLRx analyst confirms payer scope, HTA and IRA analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.